FDA to Allow Generic Companies to Alter Drug Labels

Published Online: Monday, August 5, 2013
Follow Pharmacy_Times:
The FDA intends to allow generic drug manufacturers to update product safety labels to include new information on potential risks, according to a July 4 report in USA Today.

The FDA announcement, made July 3, follows a Supreme Court ruling that struck down a lawsuit involving adverse effects from a generic medication. The 5-4 ruling follows several similar lawsuits, where the court ruled that generic manufacturers were not liable for product safety label updates after a generic is already on the market.

“When it comes to decisions on safety and approval of prescription medicine, the FDA is best equipped to make judgments that affect patients,” said GPhA President and CEO Ralph G. Neas in a release. “The experts at the FDA alone have the scientific knowledge, regulatory experience, and complete data to make these decisions.”

The FDA announcement also follows years of petitions from consumer advocacy groups requesting easier processes for label safety updates, USA Today noted.

Currently, generic manufacturers can only change product labels if the FDA approves of the changes or if the regulatory agency orders them to make changes.

According to USA Today, GPhA would prefer the labeling changes remain under the jurisdiction of the FDA.

“Decisions on safety and efficacy of prescription drugs should rest in the hands of the FDA, the only body with the scientific knowledge, regulatory experience, and complete data that is needed to make these decisions,” Neas told USA Today.

Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$